REGENXBIO INC (RGNX) Stock Income Statement
NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 156.72M | 83.33M | 90.24M | 112.70M | 470.30M | |||
| Cost Of Goods | 32.72M | 33.57M | 37.21M | 54.50M | 51.80M | |||
| Gross Profit | 124.00M | 49.76M | 53.03M | 58.20M | 418.50M | |||
| Operating Expenses | 281.35M | 280.11M | 321.16M | 321.10M | 258.60M | |||
| Research and Development | 206.76M | 208.52M | 232.27M | 242.50M | 181.40M | |||
| Selling, General, and Administrative Expenses | 73.67M | 71.62M | 88.49M | 85.30M | 79.30M | |||
| Operating Income | -157.36M | -230.34M | -268.13M | -262.90M | 160.00M | |||
| Interest Income/Expense | -333.00K | 5.34M | 4.48M | -17.50M | -18.70M | |||
| Non Recurring Items | N/A | -2.10M | N/A | N/A | N/A | |||
| Income Before Taxes | -157.69M | -227.10M | -263.65M | -280.40M | 141.20M | |||
| Income Tax | N/A | N/A | -152.00K | -100.00K | 13.40M | |||
| Net Income | -157.69M | -227.10M | -263.49M | -280.30M | 127.80M | |||
| EBITDA | -141.37M | -214.13M | -250.81M | -250.00M | 169.60M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.11 | -4.59 | -6.02 | -6.50 | 2.91 | |||
| Non GAAP EPS | -3.11 | -4.56 | -6.03 | -6.50 | 2.74 | |||
| Statistics | ||||||||
| Gross Profit Margin | 79.12% | 59.72% | 58.76% | 51.64% | 88.99% | |||
| Profit Margin | -100.62% | -272.54% | -291.99% | -248.71% | 27.17% | |||
| Operating Profit Margin | -100.41% | -276.43% | -297.12% | -233.27% | 34.02% | |||
All data in USD